Publication
Title
Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder
Author
Abstract
Introduction: Bipolar disorder is a severe, chronic psychiatric disorder with a need for long-term treatment. Patient nonadherence is frequent and poses a major problem in maintenance therapy. Aripiprazole once-monthly long-acting injectable (AOM LAI) is a recently US Food and Drug Administration-approved treatment option for maintenance therapy that could be of great value. Areas covered: This paper reviews the pharmacokinetic, efficacy and safety data for AOM LAI in bipolar disorder. Expert opinion: AOM LAI is a safe and efficacious treatment option in the maintenance therapy of bipolar I disorder. However, further research is still needed to determine the position of AOM LAI relative to other available treatment options.
Language
English
Source (journal)
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Publication
2018
Volume/pages
14:10(2018), p. 999-1005
ISI
000447620100002
Pubmed ID
30141352
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 09.11.2018
Last edited 16.09.2021
To cite this reference